CSF3 and acute myeloid leukemia: Due to the adverse risk of the XP association with AML and the profile of AML with complex karyotype and monosomy 7, which constitute factors of poor prognosis, as well as the absence of the studies conceding the tolerance of the chemotherapy by patients suffering from XP, our patient was put under low-dose cytarabine protocol with cytarabine 10 mg/m2/day (d1–d10) and granulocyte colony-stimulating factor (G-CSF): 5 μg/kg/day (d1–d10).